MREO

MREO

USD

Mereo BioPharma Group plc American Depositary Shares

$1.780-0.050 (-2.732%)

Цена в режиме реального времени

Healthcare
Биотехнология
Великобритания

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$1.830

Максимум

$1.880

Минимум

$1.780

Объем

1.12M

Фундаментальные показатели компании

Рыночная капитализация

283.2M

Отрасль

Биотехнология

Страна

United Kingdom

Статистические данные торговли

Средний объем

1.32M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $1.47Текущая $1.780Максимум $4.395

Связанные новости

PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

Просмотреть больше
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Analyst Upgrades

JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8

JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group with a Overweight and raises the price target from $7 to $8.

Просмотреть больше
JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

Просмотреть больше
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
BusinessWire

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

- Company's second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - - āshibio has exclusive license to develop and commercialize vantictumab

Просмотреть больше
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
GlobeNewswire

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12,

Просмотреть больше
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.